| 4.1977 0.078 (1.89%) | 06-10 12:14 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.78 | 1-year : | 6.52 |
| Resists | First : | 4.95 | Second : | 5.59 |
| Pivot price | 4.28 |
|||
| Supports | First : | 3.92 | Second : | 3.26 |
| MAs | MA(5) : | 4.2 |
MA(20) : | 4.29  |
| MA(100) : | 4.37 |
MA(250) : | 4.49 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.2 |
D(3) : | 22.9 |
| RSI | RSI(14): 47.2 |
|||
| 52-week | High : | 7.11 | Low : | 3.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ RCEL ] has closed above bottom band by 34.0%. Bollinger Bands are 58.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.21 - 4.25 | 4.25 - 4.27 |
| Low: | 3.88 - 3.92 | 3.92 - 3.94 |
| Close: | 4.07 - 4.13 | 4.13 - 4.17 |
AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.
Tue, 09 Jun 2026
Insider Buying: Joseph Woody Acquires 10,000 Shares of AVITA Med - GuruFocus
Tue, 09 Jun 2026
Director Woody Fralin buys 10,000 AVITA Medical (RCEL) shares - Stock Titan
Mon, 08 Jun 2026
AVITA Medical Issues Warrant to Perceptive Tied to $60 Million Credit Facility - TradingView
Fri, 05 Jun 2026
Insider Buying: Joseph Woody Acquires 10,000 Shares of AVITA Med - GuruFocus
Fri, 05 Jun 2026
[8-K] AVITA Medical, Inc. Reports Material Event - Stock Titan
Fri, 05 Jun 2026
AVITA Medical (RCEL) registers 650,000 shares tied to Perceptive $3.40 warrant - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 31 (M) |
| Shares Float | 30 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 16.8 (%) |
| Shares Short | 3,550 (K) |
| Shares Short P.Month | 3,560 (K) |
| EPS | -1.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.56 |
| Profit Margin | -62.7 % |
| Operating Margin | -45.8 % |
| Return on Assets (ttm) | -40.8 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 1.91 |
| Sales Per Share | 2.35 |
| EBITDA (p.s.) | -1.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.7 |
| PEG Ratio | 0 |
| Price to Book value | -7.65 |
| Price to Sales | 1.78 |
| Price to Cash Flow | -4.19 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|